|Dear Seed Investor,
InMed Pharmaceuticals (CSE: IN; OTCQB: IMLFF) has had quite the past few weeks with a number of game-changing announcements!
They filed a patent for their proprietary cannabinoid biosynthesis, which could unlock billions of dollars in the industry.
Why is this important? Here's a quick overview:
So what does this mean for InMed?
- Cannabinoids are naturally occuring in the human body and are vital for our health. Within the human body they are called endocannibinoids.
- Extracting cannabinoids from the cannabis plant leads to a lot of waste, as only about 2% of the plant is used.
- In order to scale extraction for cannabinoids, you have to grow a massive amount of cannabis.
- Currently the industry is only focusing on 2 main cannibinoids, THC and CBD, as they are the most abundant, but there are over 80 cannabinoids within the plant.
- These additional cannibinoids are "rare earths" that are waiting to be discovered, as they have numerous medicinal qualities.
- The problem is they cannot be commercially produced at large enough quantities at a low enough price to be used.
Well, InMed just filed a patent on their proprietary biosynthesis process that can manufacture ANY of the medical cannabinoid compounds... without ever touching the plant!!
So they not only capture the superior economics of bypassing the grow-harvest-extract-purify cycle, but is also vastly more scalable and amenable to long-term systems optimization.
InMed is now poised to do to cannabis medicine what Eli Lilly (LLY) did back in the early 1980s to the then insulin manufacturing industry. Back then Ely Lilly transformed the industry through biosynthetics and created a billion dollar plus business. InMed is gearing up to repeat this process.
As if that news wasn't big enough, last week InMed dropped another bombshell, announcing that Ben Paterson, P.E., is joining InMed as a consultant to assist in defining the pathway for the scale-up, purification, and manufacturing strategies for InMed’s cannabinoid biosynthesis program.
Again this is HUGE news! Remember Eli Lilly, who we just mentioned? Well Mr. Paterson spent 37 YEARS with Eli Lilly as their Senior Engineering Advisor, including 24 in biosynthesis.
If you are poised to be the next Eli Lilly, you might as well hire the guy who helped them scale!
And like the immortal words of Steve Jobs from Apple (AAPL) - One More Thing...
Today they announced a huge update on their biosynthesis program development. This is big news for the company, read the full release below!
InMed Continues to Make Significant Strides on Biosynthesis Program Development
Vancouver, BC – September 25, 2017 - InMed Pharmaceuticals, Inc. (“InMed” or the "Company") (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced today an update to its investors and stakeholders on the significant advancements in its proprietary technology for the microbial biosynthesis of cannabinoids.
InMed has successfully demonstrated that it can selectively produce all four “gateway” cannabinoids using genetically engineered microorganisms. These molecules can be functionalized further to produce any of the 90+ “downstream” cannabinoids found naturally in the cannabis plant. The company is actively employing this production chassis to synthesize compounds for its pharmaceutical research programs.
Eric A. Adams, President & CEO states, “Successful scale-up and commercialization of the biosynthesis process for cannabinoid production is a top priority for InMed. We are dedicating substantial resources to this project and have retained key individuals as we transition into the advanced pilot and to the commercialization phases of development. The breadth and depth of our patents, currently either submitted or being prepared for submission, will provide significant protection to the entire process.”
InMed’s biosynthesis program has resulted in two significant ‘firsts”:
- new metabolic pathway for manufacturing the terpenoid family of cannabinoid precursors that is much more robust than other microbial expression tested by InMed
- first ever production of any fully-assembled ‘downstream’ cannabinoids in E. coli, beginning with genetic material to produce all precursors, enzymes, and synthases
Microorganisms do not naturally produce cannabinoids. However, utilizing genetic engineering to modify their inner workings, InMed has systematically introduced the cannabis plant’s metabolic pathways into bacteria and yeast and has reported the first-of-its-kind production of downstream cannabinoids in these hosts. This development opens the gates for industrial-scale manufacturing of naturally occurring cannabinoids and is a quantum advance over existing manufacturing platforms such as direct extraction from cannabis or chemical synthesis. The former is quite encumbered, time-consuming and low-yielding, whereas chemical synthesis is especially challenging and expensive due to the complexity of these molecules. InMed, in consultation with industry experts, has concluded that microbial biosynthesis is superior to both approaches.
Superior to plant-sourced cannabinoids, biosynthesis is less time-consuming and less expensive, eliminating the need for planting, growing, harvesting and extracting. There are also economic and environmental savings such as substantially reduced resource requirements versus plant-sourcing (water, electricity, manpower, etc.). Furthermore, the growing process has several hard-to-remove impurities (pesticides, herbicides, fertilizers), potentially presenting significant safety issues. As with all crops, yield fluctuations present an additional risk. Only 2-3 cannabinoids can be extracted from the plant in sufficient quantities to make the process economically viable.
Adams adds, “The biosynthesis process opens up access to drug discovery and therapeutic use of all 90+ cannabinoids, most of which occur in only trace amounts in the plant and cannot be extracted in an economical fashion.”
InMed plans the following next steps for this promising technology:
- Continue to generate new patents for the biosynthesis process leading to ‘gateway’ and ‘downstream’ cannabinoids
- Optimize and validate system performance criteria with the pilot scale facility at University of British Columbia
- Produce at pilot scale several downstream cannabinoids at pharmaceutical-grade purity
- Scale-up the pilot production methods to commercial-size facility together with external vendors with extensive biosynthesis expertise
- Optimize the commercial system to maximize quantities while minimizing time/cost
InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed’s proprietary bioinformatics database assessment tool, the biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the Company.
For more information, visit www.inmedpharma.com
Contact: InMed Pharmaceuticals Inc.
Corporate Development and Investor Relations
Cautionary Note Regarding Forward-Looking Information
This news release contains "forward-looking information" and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: the viability of its biosynthesis process for manufacturing cannabinoids and the expected fundamental value drivers of the Company.
With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding biosynthesis and its processes: the patentability of the process; the successful commercial development of InMed’s biosynthesis assets; the expected fundamental value drivers of the Company; and others. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.
Additionally, there are known and unknown risk factors which could cause InMed’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: may be successful in advancement of InMed’s Biosynthesis assets; InMed’s biosynthesis assets may never be suitable for commercial production of cannabinoids; and InMed's proprietary platform technology, product pipeline and drug development programs may not return their expected level of value.
A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed’s Annual Information Form and other continuous disclosure filed with Canadian securities regulatory authorities on SEDAR at www.sedar.com. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
The Seed Investor